このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

GBPDC: Gut-Brain in PD Consortium Master Protocol (GBPDC)

2026年8月20日 更新者：Duke University

Consortium for Gut-Brain Communication in Parkinson's Disease Master Protocol

The purpose of this research study is to identify the role that the gut-brain axis, the group of nerves that connect the brain and gut, plays in Parkinson's disease (PD). The National Institute of Diabetes and Digestive and Kidney Diseases is sponsoring this research study.

During this study, specific groups of participants, also known as "cohorts", will be identified based on the severity of their PD. There will also be a cohort enrolling participants who do not have Parkinson's and a cohort enrolling participants that are at risk for developing PD. Each of these cohorts will be compared to the others to assess the differences in the gut-brain connection.

Participants in this study will:

  • meet with a medical provider
  • answer questionnaires
  • give samples of blood, stool, and saliva
  • have X-rays taken while swallowing different foods (swallowing study)
  • have X-rays taken to see how long it takes markers to move through their colon (colon transit study)
  • have a flexible sigmoidoscopy, where a doctor looks inside the lower part of the colon and takes small tissue samples (biopsies) from the mucosa (lining)
  • have samples taken of their skin
  • have an anorectal manometry and a balloon expulsion test, where a small tube and balloon are placed in the rectum to measure muscle function.

Participation in the study will last up to 24 months (2 years).

調査の概要

状態

募集

条件

詳細な説明

The objectives of the master protocol are to establish a common platform that: (1) assures the collection, integration, and analysis of a set of uniformly collected data across all participating centers, and (2) follows the objective of the Gut-Brain Parkinson's Disease Consortium (GBPDC) with the goal "to enhance our understanding of the temporal onset of GI symptoms in PD and changes in gut-brain communication that can be used to leverage the potential role of the GI tract in the pathogenesis and progression of PD and to improve patient diagnosis, care, and outcomes."

Primary Objective

1. To collect prospective cross-sectional and longitudinal participant biospecimens with temporally coordinated evaluations of GI and neurological symptoms and functions to better characterize the phenotype of people with PD versus those without.

Secondary Objectives

  1. To elucidate the biological processes and pathways relevant to the role of the GI tract in the pathogenesis and progression of PD.
  2. To characterize GI symptoms, pathology, and gut-brain communication in PD to detect early and longitudinal changes in gut function and activity that correspond to the development or progression of PD.

Exploratory Objectives

  1. To identify possible novel gut-based biomarkers (functional, molecular, etc.), diagnostic tools, and therapeutic targets.
  2. To investigate the impact of neuroimmune interactions and other pathways in the GI tract on gut-brain communication and PD risk.

In conjunction with clinical, social, and environmental characterization, biospecimen collection within the GBPDC master protocol will provide the opportunity to probe and characterize the pathophysiologic underpinnings of the gut-brain axis in PD, refine existing biomarker testing for PD, and identify new biomarkers that could allow early detection of PD or new targets for treatment.

Duke University will serve as the biorepository for the GBPDC. Participants and study site personnel will collect, process, and ship biospecimens according to the GBPDC Biorepository Manual of Procedures using standard kits assembled specifically for the GBPDC master protocol. Biospecimens will be shipped from the study sites to the GBPDC central biorepository at Duke University for accessioning, storage, tracking, and subsequent distribution for use in approved future research. Throughout the conduct of the master protocol, a portion of the biospecimens received by the GBPDC central biorepository will be transferred to the NIDDK biorepository for approved research use. Any biospecimen aliquots remaining at the GBPDC central biorepository at the termination of the GBPDC program will be transferred to the NIDDK biorepository.

Statistical Design This is a prospective, observational, longitudinal cohort study designed to characterize gut-brain communication in Parkinson's Disease. The study employs a longitudinal design, including cross-sectional analyses of baseline data, to evaluate gastrointestinal and neurological functions in participants with PD compared to household controls and a prodromal cohort, as well as comparisons among PD severity subgroups.

Study Design Features:

  • Multi-center observational study across 5 GNRCs
  • Three participant cohorts: people with PD, people with prodromal features of PD, and household controls. The PD cohort will be further classified as mild, moderate, or severe PD.
  • Longitudinal design with assessments at baseline, 6, 12, 18, and 24 months
  • Comprehensive biospecimen collection coordinated with clinical assessments
  • Household control design where controls are matched to people with PD when available

研究の種類

観察的

入学 (推定)

250

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アメリカ
    • California
      • Stanford、California、アメリカ、94305
        • 募集
        • Stanford University
        • コンタクト：
        • 主任研究者：
          • Kathleen L Poston, MD, MS
        • 主任研究者：
          • Laren S Beckers, MD
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • まだ募集していません
        • University of Chicago
        • 主任研究者：
          • Tao Xie, MD, PhD
        • 主任研究者：
          • Eugene Chang, MD
        • コンタクト：
      • Chicago、Illinois、アメリカ、60612
        • 募集
        • Rush University
        • 主任研究者：
          • Ali Keshavarzian, MD
        • コンタクト：
        • 主任研究者：
          • Christopher Goetz, MD
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02114
        • まだ募集していません
        • Massachusetts General Hospital
        • コンタクト：
        • 主任研究者：
          • Aleksander Videnovic, MD
    • Minnesota
      • Rochester、Minnesota、アメリカ、55905
        • 募集
        • Mayo Clinic
        • 主任研究者：
          • Adil Bharucha, MBBS, MD
        • コンタクト：
        • 主任研究者：
          • Rodolfo Savica, MD, PhD
    • New York
      • New York、New York、アメリカ、10027
        • まだ募集していません
        • Columbia University
        • 主任研究者：
          • Braden Kuo, MD
        • コンタクト：
    • South Carolina
      • Charleston、South Carolina、アメリカ、29425
        • まだ募集していません
        • Medical University of South Carolina
        • コンタクト：

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

サンプリング方法

非確率サンプル

調査対象母集団

Patients at the NIDDK designated Gastroenterology Neurology Research Centers

説明

Inclusion Criteria (All PD Cohorts)

  1. Aged ≥21 years old and ≤80 years old
  2. Clinical diagnosis of PD as defined by Movement Disorder Society (MDS) PD Criteria
  3. Adequate visual, hearing, cognitive, and physical ability
  4. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures. Because longitudinal participation is important to the scientific goals of the program, a "best estimate" of interest, commitment, and geographic feasibility for three years will be documented by the enrolling investigator after interview with the potential enrollee

Inclusion Criteria Controls

  1. Aged ≥21 years old and ≤80 years old
  2. No known or diagnosed neurodegenerative disease
  3. Willingness and ability to comply with scheduled visits, laboratory tests, and other study procedures
  4. Resides within the same household as person with PD

Inclusion Criteria Prodromal Cohort

  1. Aged ≥21 years old and ≤80 years old
  2. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

Exclusion Criteria (All Cohorts)

  1. Diagnosis of secondary or atypical parkinsonism

  2. Laboratory Values:

    1. Hemoglobin (Hgb) <10
    2. Platelets <70,000
    3. Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) > 2 1/2 times upper limit of normal (ULN)
    4. Moderate or severe renal disease with an estimated glomerular filtration rate (eGFR) <60 mL/min/BSA [body surface area]) calculated using the Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation, or moderate or severe hepatic impairment (alkaline phosphatase [ALP] >2.0 times the ULN and/or total bilirubin >2.0 times the ULN)
    5. Significantly above the normal range for PT/INR/PTT
  3. Currently taking anticoagulants that are deemed exclusionary by the investigator for risk of bleeding with sigmoidoscopy procedure
  4. Clinically significant cognitive impairment with a Montreal Cognitive Assessment (MOCA) score <22
  5. Clinical or laboratory findings consistent with another primary neurodegenerative disease or cognitive disorder other than PD, including but not limited to, frontotemporal lobar disease, Huntington's disease, progressive supranuclear palsy, multisystem atrophy, Creutzfeld-Jakob- Disease, Down's syndrome, cortico-basal degeneration, dementia with Lewy Bodies, Alzheimer's disease, amyotrophic lateral sclerosis, seizure disorder, stroke, or other infectious, metabolic, or systemic disease affecting the central nervous system including, but not limited to, syphilis, present hypothyroidism, present or unaddressed/treated vitamin B12 deficiency, or other screening laboratory abnormalities
  6. Suicidality, defined as active suicidal thoughts or ideation within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide
  7. Has cancer or has had a malignant tumor within the past 5 years. (Participants with stable untreated prostate cancer or treated/removed cutaneous carcinomas are not excluded.)
  8. Any medical condition or systemic disease that, in the Investigator's opinion, may either put the participant at risk because of participation in the study, influence the results or proposed analyses, or impair the participant's ability to fully participate in the study
  9. Body mass index (BMI) >35 kg/m2 or body weight <50 kg
  10. Participant is currently pregnant, breastfeeding, and/or lactating
  11. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria)
  12. History of Covid 19 (SARS-CoV-2) infection within 6 weeks prior to screening.
  13. Participants with unresolved symptoms of Covid 19 infection or ongoing cognitive or other deficits attributable to post-Covid 19 that may affect participant safety or interfere with cognitive assessments based on the Investigator's clinical judgment
  14. Either ongoing or current participation in another clinical trial with an investigational agent and have taken at least one dose of study medication, unless unblinded on placebo, within 4 weeks prior to the start of screening, or five half-lives of the investigational drug, whichever is greater. The end of a previous investigational trial is the date the last dose of an investigational agent was taken. Participation in other research studies (e.g., observational studies) may be acceptable throughout this study.
  15. History of GI surgery. (However, patients with appendicectomy, hemorrhoid surgery, and cholecystectomy will be eligible to participate).
  16. Regular use of medication that impacts the intestinal barrier (e.g., NSAID more than 3 times weekly)
  17. Has a history of Crohn's disease, ulcerative colitis, and/or other types of colitis (microscopic, lymphocytic, or collagenous colitis). Confirmed diagnosis of inflammatory bowel disease (IBD) and/or, active or uncontrolled IBD symptoms such as diarrhea, bleeding, or severe stomach pain. Treatment for IBD in the past 6 months with medicines such as steroids, biologics, or strong immune-suppressing drugs. Surgery to remove part of the bowel due to IBD. Other long-term gut diseases that cause inflammation, such as celiac disease.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

コホートと介入

グループ/コホート
Household Controls
Age-similar household controls. Household control design where controls are matched to people with PD when available.
People with Parkinson's disease
The Parkinson's Disease (PD) cohort will be further classified as mild, moderate, or severe PD as classified by Hoehn and Yahr scale.
Prodromal Parkinson's disease
People with Parkinson's Disease prodromal features. Prodromal characteristics are defined by the MDS Research Criteria for PD and include either polysomnography (PSG)-confirmed rapid eye movement sleep behavior disorder (RBD) or possible RBD (questionnaire-based), with hyposmia as defined by the University of Pennsylvania Smell Identification Test (UPSIT) ≤ 15th percentile.

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
GI influences on PD
時間枠：enrollment to end of observation at 24 months
Trait and State cross-sectional evaluation of GI influences on PD
enrollment to end of observation at 24 months
Co-associations components of the GBA
時間枠：enrollment to end of observation at 24 months
Cross-sectional co-associations components of the GBA
enrollment to end of observation at 24 months

その他の成果指標

結果測定
メジャーの説明
時間枠
GBA Disruption and Parkinson's disease Progression
時間枠：enrollment to end of observation at 24 months
GBA disruption triggered by microbiota dysbiosis (or another GI component of the GBA) predicts PD progression (both motor and non-motor dysfunction/symptoms including GI over time).
enrollment to end of observation at 24 months
GBA Disruption and Prodromal Participants
時間枠：enrollment to end of observation at 24 months
Degree of the "type" or "nature" or "form" of the GBA disruption predict development of PD in prodromal participants over time.
enrollment to end of observation at 24 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Duke University

協力者

Medical University of South Carolina
Massachusetts General Hospital
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Chicago
Columbia University
Rush University Medical Center
Stanford University

捜査官

  • 主任研究者：Lisa Wruck、Duke Clinical Research Institute

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2026年7月3日

一次修了 (推定)

2028年12月31日

研究の完了 (推定)

2028年12月31日

試験登録日

最初に提出

2026年4月29日

QC基準を満たした最初の提出物

2026年4月29日

最初の投稿 (実際)

2026年5月5日

学習記録の更新

投稿された最後の更新 (実際)

2026年8月21日

QC基準を満たした最後の更新が送信されました

2026年8月20日

最終確認日

2026年7月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • Pro00115811
  • 5U24DK140918-02 (米国 NIH グラント/契約)
  • 5U01DK140933-02 (米国 NIH グラント/契約)
  • 5U01DK140923-02 (米国 NIH グラント/契約)
  • 5U01DK140921-02 (米国 NIH グラント/契約)
  • 5U01DK140936-02 (米国 NIH グラント/契約)
  • 5U01DK140939-02 (米国 NIH グラント/契約)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

All IPD related to the GBPDC will be shared via requests submitted through the NIDDK Central Repository.

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する